Capitalization 8.65B 11.92B P/E ratio 2024 *
29.6x
P/E ratio 2025 * 30.5x
Enterprise value 8.99B 12.39B EV / Sales 2024 *
3x
EV / Sales 2025 * 2.8x
Free-Float
66.04%
Yield 2024 *
-
Yield 2025 * -
More valuation ratios * Estimated data
Dynamic Chart
1 day+1.09%
1 week-2.96%
Current month+11.76%
1 month+5.99%
3 months+6.99%
6 months-3.18%
Current year-5.47%
More quotes
1 week
291.48
Extreme 291.48
323.17
1 month
262.12
Extreme 262.12
323.17
Current year
262.12
Extreme 262.12
364.24
1 year
261.59
Extreme 261.59
431.79
3 years
261.59
Extreme 261.59
832.70
5 years
261.59
Extreme 261.59
832.70
10 years
102.71
Extreme 102.71
832.70
More quotes
Insider TitleAgeSince
Chief Executive Officer 74 88-12-31
Chief Operating Officer 64 19-04-21
Investor Relations Contact - -
Insider TitleAgeSince
Chief Executive Officer 74 88-12-31
Founder 97 51-12-31
Director/Board Member 63 17-04-24
More insiders
Add to a list
Change 5d. change 1-year change 3-years change Capi. ($)
+1.09%-2.96%-26.31%-55.31% 8.65B
+0.13%+1.66%-10.75%-38.23% 102B
+1.40%+1.57%-11.52%-6.67% 67.72B
+0.43%-3.39%-14.14%-2.65% 44.59B
-0.20%-0.50%+16.44%+84.87% 44.16B
+1.33%-10.04%+18.05%+23.91% 41.38B
-0.80%-1.54%-0.02%-7.82% 29.08B
-0.68%-4.25%+21.53%+27.48% 25.93B
-0.58%-3.93%-16.20%-17.03% 23.03B
+1.28%+1.78%-0.17%+9.05% 22.9B
Average +0.34%-1.77%-2.31%+1.76% 40.93B
Weighted average by Cap. +0.39%-1.05%-2.64%+0.24%
See all sector performances
Ratios2024 *2025 *
Net sales 2.66B 3.67B 2.8B 3.85B
Net income 294M 405M 285M 393M
Net Debt -674M -929M -828M -1.14B
More financial data * Estimated data
Logo Bio-Rad Laboratories, Inc.
Bio-Rad Laboratories, Inc. is specialized in the development, manufacturing and marketing of products used in life sciences research, clinical diagnostics and analytical chemistry. Net sales break down by activity as follows: - manufacture of clinical diagnostic tests and automated test systems (51.8%). The group also offers test kits, quality control systems and related IT systems; - manufacture of reagents, equipment and instruments for biological research (48.1%): for the separation, identification and purification of chemical and biological substances (proteins, nucleic acids, bacteria, etc.) for the proteomics, genomics research, biopharmaceuticals, cell biology and food safety markets; - other (0.1%): in particular, manufacturing of analytical instruments. At the end of 2022, the Group has 16 production sites in the United States (5), Germany (3), France (2), China (2), Poland, the United Kingdom, Switzerland and Singapore. Net sales are distributed geographically as follows: the United States (41.2%), Europe (30.4%), Asia (22.8%) and other (5.6%).
Employees
8,030
Calendar
Related indices
More about the company
Date Price Change Volume
24-07-23 305.22 $ +1.09% 210,330
24-07-22 301.92 $ +1.72% 235,083
24-07-19 296.82 $ -1.15% 298,868
24-07-18 300.27 $ -5.77% 341,724
24-07-17 318.64 $ +1.31% 217,667

Delayed Quote Nyse, July 23, 2024 at 04:00 pm

More quotes
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
305.22USD
Average target price
366.40USD
Spread / Average Target
+20.04%
Consensus

Quarterly revenue - Rate of surprise